Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $18.00 → $30.00 | In-line → Outperform | Evercore ISI |
| 10/16/2024 | $24.00 → $30.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2023 | $15.00 | Neutral | JP Morgan |
| 8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright |
| 8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler |
| 8/4/2023 | $51.00 | Outperform | SVB Securities |
| 7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI |
| 6/7/2023 | $53.00 → $46.00 | Underperform → Neutral | Wedbush |
Novocure (NASDAQ:NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and co
Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial rollout underway in the U.S. Phase 3 PANOVA-3 trial met primary endpoint, demonstrating statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tu
Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 Novocure (NASDAQ:NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "Novocure is at an exciting inflection point as we continue to expand our multi-indication TTFields treatment platf
144 - NovoCure Ltd (0001645113) (Subject)
144 - NovoCure Ltd (0001645113) (Subject)
144 - NovoCure Ltd (0001645113) (Subject)
Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial rollout underway in the U.S. Phase 3 PANOVA-3 trial met primary endpoint, demonstrating statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer Novocure (NASDAQ:NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tu
Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 Novocure (NASDAQ:NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "Novocure is at an exciting inflection point as we continue to expand our multi-indication TTFields treatment platf
Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 Novocure (NASDAQ:NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative thera
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
Evercore ISI upgraded NovoCure from In-line to Outperform and set a new price target of $30.00 from $18.00 previously
H.C. Wainwright upgraded NovoCure from Neutral to Buy and set a new price target of $30.00 from $24.00 previously
JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00